Working… Menu

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04457089
Recruitment Status : Recruiting
First Posted : July 7, 2020
Last Update Posted : January 28, 2021
Information provided by (Responsible Party):
Bobbie Jo Rimel, MD, Cedars-Sinai Medical Center

Brief Summary:
This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.

Condition or disease Intervention/treatment Phase
Recurrent Ovarian Cancer Platinum-sensitive Ovarian Cancer Drug: Simvastatin 40mg Early Phase 1

Detailed Description:
This is a pilot study of statin therapy to examine the feasibility of simvastatin use to reduce disease progression in 20 patients with platinum-sensitive ovarian cancer at Cedars-Sinai Medical Center. This study will focus on patients with recurrent platinum sensitive ovarian cancer to increase the likelihood that this population will experience recurrent disease during the 6-month intervention and follow-up. In addition, this population of patients has a narrow range of standard of care carboplatin doublet combinations that are prescribed, enabling the investigators to create a more homogenous study population. Given their high risk of developing recurrent disease, women with platinum sensitive ovarian cancer, have the potential to derive the maximum benefit from an intervention that could delay disease progression and enhance survival.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
Actual Study Start Date : January 25, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2024

Arm Intervention/treatment
Experimental: Simvastatin Drug: Simvastatin 40mg
Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
Other Name: Zocor

Primary Outcome Measures :
  1. Completion of the simvastatin intervention with at least 85% compliance [ Time Frame: From Cycle 1 Day 1 until Cycle 6 Day 28 (each cycle is 28 days) ]
    Percentage of patients who complete the simvastatin intervention with at least 85% compliance during Carboplatin and Doxil chemotherapy.

Secondary Outcome Measures :
  1. Response by CA125 [ Time Frame: From baseline until 12 months ]
    Change in serum level of CA125

  2. Progression-free survival [ Time Frame: From baseline until 12 months ]
    Duration until disease progression or death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment.
  • No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin.

Exclusion Criteria:

  • Prior or current use of any statin medication
  • Current systemic use of medications known to interact with statins
  • Current use of any other investigational agents
  • Liver disease, active cirrhosis
  • Uncontrolled intercurrent illness
  • History of chronic myopathy
  • Prior cancer other than ovarian cancer or non-melanomatous skin cancers
  • Known active infection with HIV
  • Current excessive alcohol consumption (average alcohol consumption of more than 5 drinks per day)
  • Prior exposure to doxorubicin or liposomal doxorubicin
  • Hemoglobin A1C >8.0%

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04457089

Layout table for location contacts
Contact: Cynthia Martin 310-423-2276

Layout table for location information
United States, California
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Cynthia Martin    310-423-2276   
Principal Investigator: Bobbie Jo Rimel, MD         
Sub-Investigator: Marc Goodman, PhD         
Sub-Investigator: Andrew Li, MD         
Sub-Investigator: Christine Walsh, MD         
Sub-Investigator: Kristin Taylor, MD         
Sponsors and Collaborators
Bobbie Jo Rimel, MD
Layout table for investigator information
Principal Investigator: Bobbie Jo Rimel, MD Cedars-Sinai Medical Center
Layout table for additonal information
Responsible Party: Bobbie Jo Rimel, MD, Oncologist, Cedars-Sinai Medical Center Identifier: NCT04457089    
Other Study ID Numbers: IIT2020-03-Rimel-STOV
First Posted: July 7, 2020    Key Record Dates
Last Update Posted: January 28, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Bobbie Jo Rimel, MD, Cedars-Sinai Medical Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immune System Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors